Early Benefit Assessment of Pharmaceuticals in Germany: Manufacturers' Expectations versus the Federal Joint Committee's Decisions

Conclusions. While the FJC tends to disagree with the rating of benefit by manufacturers, it softens IQWiG’s decisions, potentially to make the final outcome more acceptable. Concerns voiced that the FJC might be exceeding its statutory authority by taking cost or procedural considerations into account appear to be unfounded. Choosing appropriate evidence to submit for each endpoint remains a challenge, as submission of health outcomes evidently influences decisions.
Source: Medical Decision Making - Category: Health Management Authors: Tags: Original Articles Source Type: research